Economic Evaluation of Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diabetes is a highly prevalent and costly disease. Studies indicate that combined diet and physical activity promotion programs can prevent type 2 diabetes among persons at increased risk. PURPOSE: To systematically evaluate the evidence on cost, cost-effectiveness, and cost-benefit estimates of diet and physical activity promotion programs. DATA SOURCES: Cochrane Library, EMBASE, MEDLINE, PsycINFO, Sociological Abstracts, Web of Science, EconLit, and CINAHL through 7 April 2015. STUDY SELECTION: English-language studies from high-income countries that provided data on cost, cost-effectiveness, or cost-benefit ratios of diet and physical activity promotion programs with at least 2 sessions over at least 3 months delivered to persons at increased risk for type 2 diabetes. DATA EXTRACTION: Dual abstraction and assessment of relevant study details. DATA SYNTHESIS: Twenty-eight studies were included. Costs were expressed in 2013 U.S. dollars. The median program cost per participant was $653. Costs were lower for group-based programs (median, $417) and programs implemented in community or primary care settings (median, $424) than for the U.S. DPP (Diabetes Prevention Program) trial and the DPP Outcomes Study ($5881). Twenty-two studies assessed the incremental cost-effectiveness ratios (ICERs) of the programs. From a health system perspective, 16 studies reported a median ICER of $13 761 per quality-adjusted life-year (QALY) saved. Group-based programs were more cost-effective (median, $1819 per QALY) than those that used individual sessions (median, $15 846 per QALY). No cost-benefit studies were identified. LIMITATION: Information on recruitment costs and cost-effectiveness of translational programs implemented in community and primary care settings was limited. CONCLUSION: Diet and physical activity promotion programs to prevent type 2 diabetes are cost-effective among persons at increased risk. Costs are lower when programs are delivered to groups in community or primary care settings. PRIMARY FUNDING SOURCE: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
The Finnish Diabetes Prevention Study (DPS)
Lindström, J., Louheranta, A., Mannelin, M., Rastas, M., Salminen, V., Eriksson, J., Uusitupa, M., Tuomilehto, J., & for the Finnish Diabetes Prevention Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3230 · Cited by 1,848
Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-29 · Cited by 1,309
Self-citationHerman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
Self-citationAssessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Grosse, S. D. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.2.165 · Cited by 637
Ali, M. K., Echouffo-Tcheugui, J. B., & Williamson, D. F. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1009 · Cited by 594 · cited 1×
“Studies have also demonstrated the feasibility and effectiveness of such programs when they are implemented in primary care or community settings (9).”
BackgroundCost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491
Self-citationThe 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1468 · Cited by 436
Balk, E. M., Earley, A., Raman, G., Avendano, E. A., Pittas, A. G., & Remington, P. L. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0452 · Cited by 371 · cited 5×
“Evidence also showed that groupbased programs may achieve effectiveness similar to that for individual-based programs (10).”
BackgroundMethodResultInfluentialOckene, I. S., Tellez, T. L., Rosal, M. C., Reed, G. W., Mordes, J., Merriam, P. A., Olendzki, B. C., Handelman, G., Nicolosi, R., & Ma, Y. (2012) · American Journal of Public Health · doi:10.2105/ajph.2011.300357 · Cited by 201 · cited 2×
“The median cost per participant for translational programs delivered by trained laypersons (median, $357 [range, $191 to $839]) (21, 22, 26) was lower than that for those delivered by health professionals (median, $1077 [IQI, $381 to $1329]; 4 programs; 5 data points) (20, 28–30); howFigure 1.”
BackgroundLifestyle Interventions Are Cost-Effective in People With Different Levels of Diabetes Risk
Jacobs-van der Bruggen, M. A. M., Bos, G., Bemelmans, W. J., Hoogenveen, R. T., Vijgen, S. M., & Baan, C. A. (2007) · Diabetes Care · doi:10.2337/dc06-0690 · Cited by 137 · cited 3×
“Jacobs-van der Bruggen et al, 2007 (30); Netherlands Adults with moderate risks for diabetes, obese adults aged 30–70 y 3 y/lifetime 2 published Dutch trials Literature BMI: −0.”
BackgroundPalmer, A. J., Roze, S., Valentine, W. J., Spinas, G. A., Shaw, J. E., & Zimmet, P. Z. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90029-x · Cited by 128
Zhuo, X., Zhang, P., Gregg, E. W., Barker, L., Hoerger, T. J., Pearson-Clarke, T., & Albright, A. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1115 · Cited by 82
Self-citation
Cited by
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationEly, E. K., Gruss, S. M., Luman, E. T., Gregg, E. W., Ali, M. K., Nhim, K., Rolka, D. B., & Albright, A. L. (2017) · Diabetes Care · doi:10.2337/dc16-2099 · Cited by 386
“translation studies have demonstrated that in many cases, type 2 diabetes can be prevented or delayed for those at high risk (3,4) through a structured intervention that can be delivered cost effectively in real-world settings (5,6).”
BackgroundSelf-citationHaw, J. S., Galaviz, K. I., Straus, A. N., Kowalski, A. J., Magee, M. J., Weber, M. B., Wei, J., Narayan, K. M. V., & Ali, M. K. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.6040 · Cited by 354
“Treatment costs of type 2 diabetes (subsequently referred to as diabetes) remain a significant burden on individuals and health care systems, amounting to $245 billion in the United States alone in 2012.(3) Primary prevention of diabetes has proved to be costeffective in various populations and settings(3) and is ther…”
BackgroundProjection of the future diabetes burden in the United States through 2060
Lin, J., Thompson, T. J., Cheng, Y. J., Zhuo, X., Zhang, P., Gregg, E., & Rolka, D. B. (2018) · Population Health Metrics · doi:10.1186/s12963-018-0166-4 · Cited by 335
Self-citationA systematic review of real-world diabetes prevention programs: learnings from the last 15 years
Aziz, Z., Absetz, P., Oldroyd, J., Pronk, N. P., & Oldenburg, B. (2015) · Implementation Science · doi:10.1186/s13012-015-0354-6 · Cited by 305
Self-citation
Metadata
- Authors
- Li, R., Qu, S., Zhang, P., Chattopadhyay, S., Gregg, E. W., Albright, A., Hopkins, D., & Pronk, N. P.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2015-09-15
- Volume
- 163
- Issue
- 6
- Pages
- 452-460
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1910700299
- Cited by
- 152
- References
- 15
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.